Prospects for Treatment of Neuromyelitis Optica Spectrum Disorder Ichiro Nakashima 1 1Department of Neurology, Tohoku Medical and Pharmaceutical University Keyword: 視神経脊髄炎スペクトラム障害 , モノクローナル抗体 , B細胞 , 補体 , インターロイキン6 , neuromyelitis optica spectrum disorder , monoclonal antibody , B cell , complement , interleukin-6 pp.61-68
Published Date 2020/1/1
DOI https://doi.org/10.11477/mf.1416201478
  • Abstract
  • Look Inside
  • Reference


Neuromyelitis optica spectrum disorder (NMOSD) is a disease related to anti-aquaporin-4 antibody. Since NMOSD was once considered a phenotype of multiple sclerosis, no approved drugs are available for its treatment. In Japan, the current standard treatment for preventing relapses in patients with NMOSD is low-dose prednisolone and/or oral immuno-suppressants. There is a critical unmet need for non-steroid treatments for patients with NMOSD. Four monoclonal antibodies have completed their clinical trials in Japan and are pending approval. In this review, we summarize the results of each of these clinical trials.

Copyright © 2020, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院